Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study) - Archive ouverte HAL Access content directly
Journal Articles Lung Cancer Year : 2021

Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study)

(1) , (1) , (2) , (3, 4) , (5) , (6) , (7) , (8) , (9) , (10) , (1, 11) , (12)
1
2
3
4
5
6
7
8
9
10
11
12

Abstract

Advanced non-squamous non-small cell lung cancer (NsqNSCLC) progressing at the induction of a first-line of platin-based chemotherapy is a subgroup of patients with poor prognosis and few second-line treatment options.
Not file

Dates and versions

hal-03524385 , version 1 (13-01-2022)

Identifiers

Cite

Jean-Bernard Auliac, Isabelle Monnet, Acya Bizieux, Laurent Greillier, Margaux Geier, et al.. Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study). Lung Cancer, 2021, 161, pp.122-127. ⟨10.1016/j.lungcan.2021.09.007⟩. ⟨hal-03524385⟩
24 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More